NUVB
$4.40
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.
Recent News
RBC Capital Lifts PT on Nuvation Bio (NUVB) to $13 From $12 – Here’s Why
Nuvation Bio Inc. (NYSE:NUVB) is one of the best penny stocks to buy according to Reddit. On March 3, RBC Capital cut the price target on Nuvation Bio Inc. (NYSE:NUVB) to $13 from $12 while maintaining an Outperform rating on the shares. The rating update came after the company reported its fiscal Q4 results, with […]
Nuvation Bio Inc. Q4 2025 Earnings Call Summary
Moby summary of Nuvation Bio Inc.'s Q4 2025 earnings call
Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch
Nuvation Bio Inc. (NYSE:NUVB) is one of the best low cost stocks to buy under $5. On March 2, Nuvation Bio (NUVB) reported a pivotal 2025 marked by the FDA approval and rapid commercial launch of Ibtrozi (Taletrectinib) for ROS1-positive non-small cell lung cancer. With 432 new patient starts by year-end, the drug’s uptake outpaced […]
Nuvation Bio Transitions To Commercial Stage With Iptrozi And Safusidenib Progress
Nuvation Bio (NYSE:NUVB) received full U.S. FDA approval for its first oncology therapy, Iptrozi, for advanced ROS1-positive non-small cell lung cancer. The company has commercially launched Iptrozi in the U.S. with early reports of strong adoption. Nuvation Bio entered an exclusive licensing partnership with Eisai for Iptrozi in Europe. The company also finalized a clinical protocol amendment for safusidenib in IDH1-mutant glioma, aligning with an accelerated approval path. Nuvation Bio is...
SSR Mining Stock Up 180% as New $5 Million Stake Signals Gold Conviction
SSR Mining runs a diversified portfolio of gold, silver, and base metal mines across four continents with a vertically integrated model.